Reduction in caffeine withdrawal after open-label decaffeinated coffee

被引:1
|
作者
Mills, Llewellyn [1 ,2 ]
Lee, Jessica C. [3 ]
Boakes, Robert [4 ]
Colagiuri, Ben [4 ]
机构
[1] Univ Sydney, Cent Clin Sch, Discipline Addict Med, Griffith Taylor Bldg A19,Manning Rd, Sydney, NSW 2006, Australia
[2] South Eastern Sydney Local Hlth Dist, Drug & Alcohol Serv, Sydney, NSW, Australia
[3] Univ New South Wales, Sch Psychol, Sydney, NSW, Australia
[4] Univ Sydney, Sch Psychol, Sydney, NSW, Australia
关键词
Withdrawal; addiction; caffeine; expectancy; placebo; DOUBLE-BLIND; CONDITIONED PLACEBO; SMOKING WITHDRAWAL; SYMPTOMS; ALCOHOL; EXPECTANCY; RELAPSE; DEPENDENCE; ANALGESIA; RESPONSES;
D O I
10.1177/02698811221147152
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Withdrawal from addictive drugs can be reduced by administering placebo deceptively, but in the clinic it is unethical to deceive the patient. Open-label placebo effects have been observed across a range of psychophysiological phenomena, and may also apply to drug withdrawal. Method: 24-hour abstinent heavy coffee drinkers (N = 61) rated their caffeine withdrawal symptoms before being allocated to one of three groups. The Deceptive group was given decaffeinated coffee (decaf) and told it was caffeinated, the Open-Label group given decaf and told it was decaf and the Control group given water and told it was water. After 45 min, caffeine withdrawal was measured again. All participants rated their expectancies of withdrawal reduction from caffeinated coffee, decaf and water prior to being randomised and the end of the study. Results: There was a significant 9.5-point reduction in caffeine withdrawal in the Open-Label group (95% confidence interval (CI): 4.7, 14.3; p = 0.002), which was 8.6 points less than the Deceptive group (95%CI: 0.4, 16.8; p = 0.014) but 8.9 points greater than the Control group (95%CI: 0.6, 17.2; p = 0.012). Pre-randomisation, participants expected caffeinated coffee to reduce their withdrawal symptoms the most, followed by water and decaf, Pre-randomisation expectancy of withdrawal was only associated with amount of withdrawal reduction in the Deceptive group. Conclusion: It appears as if open-label placebo caffeine (i.e. decaf) can reduce caffeine withdrawal symptoms, even when people do not hold a conscious expectancy it will do so. There may be ways to integrate open-label placebo procedures into clinical interventions for drug dependence without violating informed consent.
引用
收藏
页码:181 / 191
页数:11
相关论文
共 50 条
  • [1] Caffeine content of decaffeinated coffee
    McCusker, Rachel R.
    Fuehrlein, Brian
    Goldberger, Bruce A.
    Gold, Mark S.
    Cone, Edward J.
    JOURNAL OF ANALYTICAL TOXICOLOGY, 2006, 30 (08) : 611 - 613
  • [2] How is caffeine removed to produce decaffeinated coffee?
    Clydesdale, FM
    SCIENTIFIC AMERICAN, 2002, 287 (04) : 107 - 107
  • [3] A MORE ACCURATE METHOD FOR DETERMINATION OF CAFFEINE IN DECAFFEINATED COFFEE
    YERANSIAN, JA
    KADIN, H
    STEIANUC.A
    BORKER, E
    JOURNAL OF THE ASSOCIATION OF OFFICIAL AGRICULTURAL CHEMISTS, 1963, 46 (02): : 315 - +
  • [4] Optimisation of a CE method for caffeine analysis in decaffeinated coffee
    Meinhart, Adriana Dillenburg
    Bizzotto, Carolina Schaper
    Ballus, Cristiano Augusto
    Prado, Marcelo Alexandre
    Bruns, Roy Edward
    Teixeira Filho, Jose
    Godoy, Helena Teixeira
    FOOD CHEMISTRY, 2010, 120 (04) : 1155 - 1161
  • [5] Estimation of Caffeine Concentration in Decaffeinated Coffee and Tea Available in Pakistan
    Sadiq, Muhammad Abbas
    Zohra, Effat
    Jamil, Muhammad Adnan
    Wasim, Muhammad
    Riaz, Humayun
    Raza, Syed Atif
    Aslam, Muhammad Shahzad
    Hussain, Shahzad
    Javed, Osama
    Ahmad, Muhammad Ayaz
    JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2018, 12 (01): : 229 - 247
  • [6] HEADACHE CAUSED BY CAFFEINE WITHDRAWAL AMONG MODERATE COFFEE DRINKERS SWITCHED FROM ORDINARY TO DECAFFEINATED COFFEE - A 12 WEEK DOUBLE-BLIND TRIAL
    VANDUSSELDORP, M
    KATAN, MB
    BRITISH MEDICAL JOURNAL, 1990, 300 (6739): : 1558 - 1559
  • [7] Lithium carbonate in the management of cannabis withdrawal in humans: an open-label study
    Winstock, A. R.
    Lea, T.
    Copeland, J.
    JOURNAL OF PSYCHOPHARMACOLOGY, 2009, 23 (01) : 84 - 93
  • [8] Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome
    Trenkwalder, Claudia
    Stiasny-Kolster, Karin
    Kupsch, Andreas
    Oertel, Wolfgang H.
    Koester, Juergen
    Reess, Juergen
    MOVEMENT DISORDERS, 2006, 21 (09) : 1404 - 1410
  • [9] Levetiracetam for the treatment of alcohol withdrawal syndrome: An open-label pilot trial
    Krebs, Michael
    Leopold, Karolina
    Richter, Christoph
    Kienast, Thorsten
    Hinzpeter, Axel
    Heinz, Andreas
    Schaefer, Martin
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2006, 26 (03) : 347 - 349
  • [10] RAPID-DETERMINATION OF CAFFEINE IN COFFEE AND DECAFFEINATED COFFEE BY HIGH-PRESSURE LIQUID-CHROMATOGRAPHY
    ATTINA, M
    CIRANNI, G
    FARMACO-EDIZIONE PRATICA, 1976, 31 (12): : 650 - 656